Subcutaneous Immunotherapy Articles & Analysis
3 news found
Any patient who would be adversely impacted by a discontinuation period in their subcutaneous immunotherapy (SCIT aka allergy shots) is eligible. About Oral Mucosal Immunotherapy (OMIT) Respiratory allergies affect at least 60 million people in the United States, resulting in 11.1 million visits to the doctor in 2010. 100 million Europeans ...
Allerdent® is a patented oral mucosal immunotherapy (OMIT) system that uses a specially formulated, fully-functional toothpaste into which proteins, such as FDA-approved respiratory immunotherapy agents, can be stably incorporated. ...
These claims provide patent protection for the oral mucosal immunotherapy (OMIT) platform. OMIT enables regular administration of allergy immunotherapy while a user brushes their teeth. ...